Building a score to predict clots and bleeding in people with cancer-associated thrombosis
Develops a risk score for repeat clots and bleeding in cancer-associated thrombosis.
Key facts
- Who runs it
- Ottawa Hospital Research Institute
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 3 Dec 2024
- Expected to end
- Dec 2027
- Type of study
- Observational
- Record updated
- 25 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active cancer who have a blood clot in a vein and will take blood thinners for at least 6 months.
- Age
- 18 years and older
- Sex
- All
- Disease stage
- Active cancer of any type, with a confirmed blood clot: deep vein clot in an arm or leg (DVT), lung clot (PE), clot in belly veins (splanchnic vein thrombosis) or in brain veins (cerebral sinus vein thrombosis). Expected life span over 6 months.
- Earlier treatment
- Planned treatment of the clot for at least 6 months with blood thinners (anticoagulants) by injection or by mouth, at full treatment dose.
Main reasons for not taking part
- Clots in unusual places: gonadal, ovarian or retinal veins
- Clot only in a surface vein (superficial vein thrombosis)
- Refusing consent after more than 72 hrs on blood thinners
- Younger than 18 years
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types
- Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing
- Estimated life expectancy > 6 months
- Willingness to give an informed consent
- Age ≥ 18 years
Who cannot take part
- Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis)
- Superficial vein thrombosis
- Age < 18 years old
- Refusal of informed consent > 72 hrs of anticoagulants
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
- Plain-language title
- Building a score to predict clots and bleeding in people with cancer-associated thrombosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 25 March 2025